FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Piliero

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Procedures

Living Beings

HIV-1
HIV

Concepts & Ideas

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Anita A Mathias; John Hinkle; Gong Shen; Jeffrey Enejosa; Peter J Piliero; Vanitha Sekar; Rebecca Mack; Frank Tomaka; Brian P Kearney
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Joseph C Gathe; Gerald Pierone; Peter J Piliero; Keikawus Arastéh; Rafael Rubio; Richard G Lalonde; David Cooper; Adriano Lazzarin; Veronika M Kohlbrenner; Catherine Dohnanyi; John Sabo; Douglas Mayers
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
Michael Sension; Peter J Piliero
Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Piliero (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Anita A Mathias; John Hinkle; Gong Shen; Jeffrey Enejosa; Peter J Piliero; Vanitha Sekar; Rebecca Mack; Frank Tomaka; Brian P Kearney
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Journal of acquired immune deficiency syndromes (1999) 2008;49(2):156-62.
2007: Joseph C Gathe; Gerald Pierone; Peter J Piliero; Keikawus Arastéh; Rafael Rubio; Richard G Lalonde; David Cooper; Adriano Lazzarin; Veronika M Kohlbrenner; Catherine Dohnanyi; John Sabo; Douglas Mayers
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
AIDS research and human retroviruses 2007;23(2):216-23.
2007: Michael Sension; Peter J Piliero
Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
The Journal of the Association of Nurses in AIDS Care : JANAC 2007;18(1):36-47.
2006: Edwin DeJesus; Peter J Piliero; Kim Summers; Mary Beth Wire; Daniel S Stein; Amanda Masterman; Yu Lou; Sherene S Min; Mark J Shelton
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 2006;50(9):3157-9.
2006: Melanie Thompson; Edwin DeJesus; Gary J Richmond; David Wheeler; John Flaherty; Peter J Piliero; Andrea True; Yu-Yuan Chiu; Ying Zhang; Emily McFalls; G Diego Miralles; Indravadan H Patel
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
AIDS (London, England) 2006;20(3):397-404.
2005: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary E O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph DeMasi; Jain Chung; Miklos Salgo
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Jacob P Lalezari; Melanie Thompson; Priny Kumar; Peter J Piliero; Richard Davey; Kristine Patterson; Anne Shachoy-Clark; Kimberly K Adkison; James Demarest; Yu Lou; M Michelle Berrey; Stephen C Piscitelli
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
AIDS (London, England) 2005;19(14):1443-8.
2005: Jonathan Leith; Peter J Piliero; Stephen Storfer; Douglas Mayers; Ralf Hinzmann
Appropriate use of nevirapine for long-term therapy.
The Journal of infectious diseases 2005;192(3):545-6; author reply 546.
2005: Michael L Tapper; Eric S Daar; Peter J Piliero; Kimberly Smith; Corklin R Steinhart
Strategies for initiating combination antiretroviral therapy.
AIDS patient care and STDs 2005;19(4):224-38.
2004: Peter J Piliero
Developments in HIV treatments: strategies for success.
The AIDS reader 2004;14(12):655-65.
2004: Peter J Piliero
Atazanavir: A novel once-daily protease inhibitor.
Drugs of today (Barcelona, Spain : 1998) 2004;40(11):901-12.
2004: Peter J Piliero
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S2-S12.
2004: Pedro Cahn; José M Gatell; Kathleen Squires; Lisa D Percival; Peter J Piliero; Ian A Sanne; Sarah Shelton; Adriano Lazzarin; Linda Odeshoo; Thomas D Kelleher; Alexandra Thiry; Michael D Giordano; Stephen M Schnittman
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2004;3(3):92-8.
2004: Mary Beth Wire; Charles Ballow; Sandra L Preston; Craig W Hendrix; Peter J Piliero; Yu Lou; Daniel S Stein
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
AIDS (London, England) 2004;18(6):897-907.
2004: Peter J Piliero; Grace A McComsey
Buffalo hump: what the experts suggest.
AIDS clinical care 2004;16(3):22-3.
2004: Peter J Piliero; Lydia Estanislao; David Simpson
Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man.
Neurology 2004;62(1):154-5.
2003: Peter J Piliero; M Hubbard; J King; John J Faragon
Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(10):1374-7.
2003: Sandra L Preston; Peter J Piliero; John Bilello; Daniel S Stein; William T Symonds; George L Drusano
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
Antimicrobial agents and chemotherapy 2003;47(11):3393-9.
2003: Sandra L Preston; Peter J Piliero; George L Drusano
Pharmacodynamics and clinical use of anti-HIV drugs.
Infectious disease clinics of North America 2003;17(3):651-74.
2003: John J Faragon; Peter J Piliero
Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs.
The AIDS reader 2003;13(9):433-4, 437-41, 446-50.
2003: Peter J Piliero; Joseph P Colagreco
Simplified regimens for treating HIV infection and AIDS.
Journal of the American Academy of Nurse Practitioners 2003;15(7):305-12.
2003: David W Haas; Carlos Zala; Shannon Schrader; Peter J Piliero; Hans Jaeger; Danilo Nunes; Alexandra Thiry; Steven Schnittman; Michael Sension
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
AIDS (London, England) 2003;17(9):1339-49.
2003: Peter J Piliero
Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
MedGenMed : Medscape general medicine 2003;5(2):1.
2003: Peter J Piliero
Editorial comment: fewer prescribing errors in the 21st Century?
The AIDS reader 2003;13(6):277.
2003: Jacob P Lalezari; Keith Henry; Mary E O'Hearn; Julio S G Montaner; Peter J Piliero; Benoit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine 2003;348(22):2175-85.
2003: Mireya Diaz; Daniel C Douek; Hernan Valdez; Brenna J Hill; Dolores Peterson; Ian Sanne; Peter J Piliero; Richard A Koup; Sylvan B Green; Steven Schnittman; Michael M Lederman
T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment.
AIDS (London, England) 2003;17(8):1145-9.
2003: Peter J Piliero; Douglas G Fish; Sandra Preston; Donna Cunningham; Tosca Kinchelow; Miklos Salgo; Jiang Qian; George L Drusano
Guillain-Barré syndrome associated with immune reconstitution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(9):e111-4.
2003: Peter J Piliero
Early factors in successful anti-HIV treatment.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2003;2(1):10-20.
2003: Ian Sanne; Peter J Piliero; Kathleen Squires; Alexandra Thiry; Steven Schnittman
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(1):18-29.
2002: Peter J Piliero; Elizabeth R Jenny-Avital
Antiretroviral rounds. Failure to achieve full virologic suppression.
AIDS clinical care 2002;14(11):100-1.
2002: Peter J Piliero; John J Faragon
Case report. Hepatitis B virus and HIV coinfection.
The AIDS reader 2002;12(10):443-4, 448-51.
2002: Peter J Piliero
Atazanavir: a novel HIV-1 protease inhibitor.
Expert opinion on investigational drugs 2002;11(9):1295-301.
2002: Peter J Piliero; Andrew G Gianoukakis
Ritonavir-associated hyperparathyroidism, osteopenia and bone pain.
AIDS (London, England) 2002;16(11):1565-6.
2002: Peter J Piliero
Interaction between ritonavir and statins.
The American journal of medicine 2002;112(6):510-1.
2002: Peter J Piliero
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
AIDS (London, England) 2002;16(5):799-800.
2002: John J Faragon; Bonnie D Purdy; Peter J Piliero
An assessment of herbal therapy use, adherence and utilization of pharmacy services in HIV clinics.
Journal of herbal pharmacotherapy 2002;2(1):27-37.
2001: Peter J Piliero; B Purdy
Nevirapine-induced hepatitis: a case series and review of the literature.
The AIDS reader 2001;11(7):379-82.
2001: Brian M Sadler; Peter J Piliero; Sandra L Preston; P P Lloyd; Yu Lou; Daniel S Stein
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
AIDS (London, England) 2001;15(8):1009-18.
2001: Peter J Piliero; D G Fish
Isoniazid-induced beta-hydroxybutyric acidosis.
Annals of internal medicine 2001;134(9 Pt 1):799.
2000: D Nunes; Peter J Piliero
Antiretroviral rounds. A co-infection treatment dilemma.
AIDS clinical care 2000;12(7):58-9.